Abbott Laboratories (ABT) Files Form 4 Insider Selling : Jared Watkin Sells 552 Shares

Abbott Laboratories (ABT): Jared Watkin , Senior Vice President of Abbott Laboratories sold 552 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were sold at $37.63 per share for a total value of $20,770.10 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, Brian B Yoor (Senior Vice President and CFO) sold 565 shares at $39.49 per share price.On Apr 29, 2016, Deepak S. Nath (Senior Vice President) sold 53 shares at $41.31 per share price.Also, On Mar 2, 2016, Robert B Ford (Executive Vice President) sold 1,706 shares at $39.28 per share price.On Mar 2, 2016, Stephen R Fussell (Executive Vice President) sold 1,402 shares at $39.26 per share price.

Shares of Abbott Laboratories (ABT) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.23 points or -0.61% at $37.43 with 77,16,278 shares getting traded. Post opening the session at $37.75, the shares hit an intraday low of $37.4 and an intraday high of $37.87 and the price vacillated in this range throughout the day. The company has a market cap of $54,990 M and the number of outstanding shares has been calculated to be 1,46,91,52,000 shares. The 52-week high of Abbott Laboratories is $51.74 and the 52-week low is $36.

Abbott Laboratories Money Flow Index Chart

On Jun 10, 2016, Abbott Laboratories announced a cash dividend of $0.2600. The company’s management has announced Jul 13, 2016 as the ex-dividend date and fixed the record date on Jul 15, 2016. The payable date has been fixed on Aug 15, 2016.

Company has been under the radar of several Street Analysts.Abbott Laboratories is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 48 from a previous price target of $45 .The Rating was issued on Apr 11, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.